Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects

Basit Öğe Kaydı
dc.authorid0000-0001-6986-3638
dc.authorid0000-0001-5912-9392
dc.authorid0000-0003-0018-2206
dc.contributor.authorDoğrukol-Ak, Dilek
dc.contributor.authorTöre, Fatma
dc.contributor.authorTuncel, Neşe
dc.date.accessioned2021-06-23T19:18:05Z
dc.date.available2021-06-23T19:18:05Z
dc.date.issued2004
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractIn recent years, VIP/PACAP/secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP(1)), GLP(2), gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and ill various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. Oil the other hand, some of the members of this family that present in the brain, call cross from brain to blood and reach the peripheral tat-gets. VIP, secretin, GLP(1), and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP(2) and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP/PACAP/secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits ill various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.en_US
dc.identifier.doi10.2174/1381612043384934
dc.identifier.endpage1340en_US
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.issue12en_US
dc.identifier.pmid15134484en_US
dc.identifier.startpage1325en_US
dc.identifier.urihttps://doi.org/10.2174/1381612043384934
dc.identifier.urihttps://hdl.handle.net/20.500.12491/5635
dc.identifier.volume10en_US
dc.identifier.wosWOS:000221066100004en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTöre, Fatma
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Pharmaceutical Designen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFamilyen_US
dc.subjectVIP
dc.subjectPACAP
dc.subjectSecretin
dc.subjectBlood Brain Barrier
dc.titlePassage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effectsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
dilek-dogrukol-ak.pdf
Boyut:
125.28 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu